Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Hans Baldau, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Sale of the M/V Diamantis P. A wholly owned subsidiary of Euroseas sold the M/V Diamantis P for ~$13.2 million and delivered the vessel to its new owners on January 15. Recall that the Diamantis P is a feeder containership that was built in 1998. The transaction is expected to result in a gain on sale of ~$10.2 million.
Spin-off transaction. Recall that Euroseas announced its intention to spin off three of its subsidiaries, two owning the M/V Aegean Express and M/V Joanna, and one that owned the M/V Diamantis P (prior to its sale) into Euroholdings Ltd. In exchange, Euroseas will receive 100% of the shares of Euroholdings Ltd., which will then be distributed to its shareholders (please refer to our note dated January 3 for transaction details).
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Key Points: – Jefferies cut Apple to “Underperform” with a price target of $200.75, while Loop Capital downgraded it to “Hold” at $230. – Declining sales in China and a 1% dip in market share are major concerns for Apple’s flagship product. – Apple’s AI initiatives, including Apple Intelligence, have not generated the anticipated sales supercycle, dampening investor enthusiasm.
Apple Inc. (AAPL) is grappling with significant challenges as analysts issue downgrades to its stock, citing weaker-than-expected iPhone sales and underwhelming performance in its artificial intelligence (AI) initiatives. The stock fell 3.82% on Tuesday following these reports, adding to mounting concerns about the tech giant’s ability to sustain its growth trajectory in an increasingly competitive market.
Jefferies analyst Edison Lee downgraded Apple to “Underperform” and slashed the price target to $200.75, a 13% reduction. Meanwhile, Loop Capital downgraded the stock from “Buy” to “Hold” and revised its target to $230, down from $275. Both firms point to headwinds in Apple’s core iPhone business and tepid consumer interest in AI-powered products as key factors behind their decisions.
The iPhone, which accounts for over half of Apple’s total revenue, is facing significant challenges. According to Jefferies, iPhone sales in China dropped by 15% to 20% year over year. This decline reflects both increased competition from local players like Huawei and Xiaomi and cautious consumer spending amid a slower Chinese economic recovery.
China has long been a critical market for Apple, contributing $66.9 billion in revenue in 2024, despite an 8% decline compared to the previous year. However, the company’s difficulties in this region are not new; Apple has struggled with currency fluctuations and declining sales for the past two years.
Globally, Apple’s iPhone market share fell by roughly 1% in Q4, landing at 23%, even as overall smartphone shipments rose by 3%. These numbers, provided by Canalys and IDC, underscore the growing competition Apple faces as it tries to maintain dominance in a crowded market.
Apple’s push into AI has also been a point of contention among analysts. The company debuted its AI platform, Apple Intelligence, in October 2024, marketing it as a transformative tool for its flagship devices. However, the staggered rollout has led to confusion among consumers, with many unaware of the platform’s full capabilities.
Jefferies had predicted that Apple Intelligence would drive a “sales supercycle,” but early indications suggest that adoption has been slow. This is a stark contrast to the success of other tech giants like Alphabet and Meta, whose innovative AI initiatives have helped drive their stock prices up 30% and 36%, respectively, over the past year.
The slow uptake of AI-powered devices further complicates Apple’s outlook, as the company seeks to diversify its revenue streams beyond the iPhone. While Apple’s Services segment remains a bright spot, generating $96.1 billion in 2024, the company will need to demonstrate sustained growth in other areas to regain investor confidence.
Despite these challenges, Apple has several opportunities to stabilize its position. The upcoming launch of a new iPhone SE, entry-level iPads, and MacBook Airs may provide a much-needed boost in mid-range and budget segments. Additionally, Apple’s brand loyalty and reputation for innovation could help it weather short-term setbacks.
The company is set to report its first-quarter earnings on January 30. Analysts and investors will be watching closely to see if Apple can reverse its recent trends and reestablish itself as a leader in both hardware and emerging technologies like AI.
SASKATOON, Saskatchewan, Canada, January 16, 2025 – MustGrow Biologics Corp. (TSXV:MGRO) (OTC:MGROF) (FRA:0C0) (the “Company” or “MustGrow“) is pleased to announce the closing of the previously announced non-brokered private placement of units (each, a “Unit“) at a price per Unit of $1,000 for aggregate gross proceeds to the Company of $2,585,000 (the “Private Placement“) on January 16, 2025 (the “Closing Date“).
Each Unit is comprised of: (i) $1,000 principal amount of unsecured convertible debentures (the “Debentures“); and (ii) 666 common share purchase warrants (the “Unit Warrants“). Each Debenture may, at the option of the holder: (i) be converted into common shares in the capital of the Company (the “Common Shares“) at price of $1.50 per Common Share (the “Principal Conversion Price“) at any time; or (ii) paid in cash 60 months following the Closing Date (subject to certain acceleration rights). Each Unit Warrant is exercisable by the holder thereof to acquire one Common Share at a price of $1.90 per Common Share for a period of 60 months following the Closing Date. The Debentures accrue interest at a rate of 8% per annum, payable semi-annually in cash.
If, at any time following the date that is 12 months from the Closing Date, the daily volume weighted average trading price of the Common Shares on the TSX Venture Exchange (the “TSXV“) is greater than $3.00 for the preceding 30 consecutive trading days, the Company shall have the option to immediately accelerate the conversion of the Debentures at the Principal Conversion Price.
In connection with the Private Placement, certain finders received an aggregate cash fee of $67,200. In addition, the Company issued to certain finders an aggregate of 44,800 non-transferable finder’s warrants (the “Finder Warrants“). Each Finder Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of $1.90 per Common Share for a period of 24 months following the Closing Date.
The Company intends to use the proceeds from the Private Placement for inventory production for TerraSanteTM, working capital and general corporate purposes.
The Debentures, the Unit Warrants, the Finder Warrants, and any underlying Common Shares issued pursuant to those securities are subject to a four month plus one day hold period from the Closing Date. The Private Placement remains subject to final approval of the TSX Venture Exchange (the “TSXV“).
Certain insiders of the Company have subscribed for 300 Units under the Private Placement for aggregate gross proceeds of $300,000. Each subscription by an “insider” is considered to be a “related party transaction” for purposes of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). The Company did not file a material change report more than 21 days before the Closing Date as the details of the Private Placement and the participation therein by each “related party” of the Company were not settled until shortly prior to the closing of the Private Placement, and the Company wished to close the Private Placement on an expedited basis for sound business reasons. The Company is relying on exemptions from the formal valuation and minority shareholder approval requirements available under MI 61-101. The Company is exempt from the formal valuation requirement in section 5.4 of MI 61-101 in reliance on section 5.5(a) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Company’s market capitalization. Additionally, the Company is exempt from minority shareholder approval requirement in section 5.6 of MI 61-101 in reliance on section 5.7(b) of MI 61-101 as the fair market value of the transaction, insofar as it involves interested parties, is not more than the 25% of the Company’s market capitalization.
This press release does not constitute, and shall not be construed as, an offer to sell or a solicitation of an offer to buy any Units within the United States.
About MustGrow
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company’s proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, and foliar products. These products are synergistically distributed alongside MustGrow’s wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow’s wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through on the commercialization and expansion of its intellectual property portfolio of approximately 112 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a public traded company (TSXV-MGRO) and has approximately 51.6 million common shares issued and outstanding and 59.2 million shares fully diluted. For further details, please visit www.mustgrow.ca.
Contact Information
Corey Giasson Director & CEO Phone: +1-306-668-2652 info@mustgrow.ca
MustGrow Forward-Looking Statements
Certain statements included in this news release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved”. Examples of forward-looking statements in this news release include, among others, statements MustGrow makes regarding: the receipt of final approval of the TSXV; and the use of proceeds from the Private Placement. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include: the receipt of final approval by the TSXV and those risks described in more detail in MustGrow’s Annual Information Form for the year ended December 31, 2023 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
Neither the TSXV, nor their Regulation Services Provider (as that term is defined in the policies of the TSXV), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
In a landmark decision, the Supreme Court has upheld a law that would effectively ban TikTok in the United States by January 19 unless the social media platform is sold to an owner not controlled by a foreign adversary. The ruling places the fate of the app, used by 170 million Americans, in the hands of President-elect Donald Trump, who takes office on January 20.
The Court sided with the government’s position that ByteDance’s ties to China pose national security concerns, rejecting TikTok’s First Amendment arguments. While acknowledging the platform’s significance, the Court emphasized Congress’s authority to address national security threats. “There is no doubt that, for more than 170 million Americans, TikTok offers a distinctive and expansive outlet for expression, means of engagement, and source of community,” the Court stated, but concluded that the security concerns outweighed these considerations.
Trump, who previously promised to “save TikTok,” now holds significant influence over the app’s future. “It ultimately goes up to me, so you’re going to see what I’m going to do,” Trump told CNN following the Court’s decision. He has reportedly discussed the matter with Chinese President Xi Jinping and is considering various options, including an executive order that would delay the ban’s enforcement by 60 to 90 days.
The implementation of the ban would have far-reaching consequences for the tech industry. Major companies like Apple and Google would be prohibited from offering TikTok in their app stores, while cloud providers such as Microsoft, Amazon, and Oracle would be barred from hosting the service. Violations could result in penalties of up to $5,000 for each instance of US user access.
Several potential solutions have emerged as stakeholders scramble to prevent a shutdown. Chinese officials have reportedly discussed selling TikTok’s US operations to Elon Musk, owner of X, although their preference is to maintain ByteDance’s ownership. Additionally, a consortium led by billionaire Frank McCourt Jr. and including “Shark Tank” star Kevin O’Leary has expressed interest in acquiring the platform for up to $20 billion. “There’s a deal to be made here so that US TikTok can stay in business,” McCourt stated recently.
The ruling’s impact extends beyond TikTok itself, potentially reshaping the competitive landscape of social media. Industry analysts predict significant benefits for established platforms if TikTok exits the US market. William Blair research analyst Ralph Schackart estimates that Meta’s Instagram could capture 60-70% of TikTok’s advertising revenue, noting that Instagram “monetizes at around 3x the rate of TikTok.” Similarly, Morgan Stanley projects that YouTube’s Shorts platform could gain $400-750 million in ad revenue for every 10% of former TikTok user time it captures.
As the situation develops, legislative solutions are also being explored. Senator Ed Markey has introduced a bill that would extend the divestiture deadline by 270 days, potentially providing crucial additional time for negotiations. Trump’s incoming administration has multiple options, including pushing Congress to overturn the law, encouraging an extension of the deadline, or facilitating a sale of the US operations.
As the January 19 deadline approaches, the tech industry, millions of users, and the advertising market await clarity on whether Trump’s administration will enforce the ban, negotiate a sale, or find another solution to keep the popular platform operating in the United States. The outcome of this high-stakes situation will likely set important precedents for foreign-owned technology companies operating in the US market.
Key Points: – Bitcoin hits $104,000, marking a 420% increase from its $20,000 price two years ago – Trump names David Sacks as crypto “czar” and plans regulatory overhaul – Administration aims to create $21 billion Strategic Bitcoin Reserve
Bitcoin’s price surged past $100,000 on Friday as cryptocurrency markets anticipate major policy shifts under President-elect Donald Trump’s incoming administration. The world’s leading cryptocurrency rose approximately 5% to $104,000, reflecting growing optimism about Trump’s promised pro-crypto agenda.
Trump, who once dismissed bitcoin as a “scam,” has undergone a dramatic shift in his stance toward digital currencies. His campaign promises include transforming the United States into the global “crypto capital,” with specific plans for industry-friendly regulations and the establishment of a government cryptocurrency stockpile.
The president-elect has already begun assembling a team of crypto advocates for key positions, including David Sacks as the administration’s cryptocurrency “czar” and Bo Hines as executive director of the Presidential Council of Advisers for Digital Assets. Paul Atkins, Trump’s pick to lead the SEC, has been a vocal supporter of cryptocurrencies, signaling a stark departure from the regulatory approach of the Biden administration.
One of Trump’s most ambitious proposals is the creation of a Strategic Bitcoin Reserve, which would require the Treasury Department to maintain at least $21 billion in bitcoin through its Exchange Stabilization Fund. This initiative would represent a significant shift in government policy, as historically, the U.S. has auctioned off cryptocurrency seized in law enforcement operations.
The cryptocurrency industry, which felt targeted by outgoing SEC Chairman Gary Gensler’s enforcement actions, has welcomed these developments. Peter Van Valkenburgh, executive director of Coin Center, expressed optimism about the expected “tone change at the SEC” under the new administration.
The industry’s enthusiasm is evident in the organization of the first-ever “Crypto Ball,” a sold-out celebration featuring “an elite lineup of musical entertainment” to mark the inauguration of what supporters are calling the first “crypto president.”
However, critics continue to raise concerns about cryptocurrency’s volatile nature and its potential use in illegal activities. Despite these reservations, bitcoin has demonstrated remarkable resilience, with its value increasing dramatically from around $20,000 two years ago to its current record levels.
As Trump prepares to take office on January 20, the cryptocurrency market eagerly awaits the implementation of his promised policies, which could reshape the regulatory landscape for digital assets in the United States.
Key Points: – The average rate on a 30-year mortgage has risen to 7.04%, its highest level since May, marking its fifth consecutive increase. – Higher mortgage rates, driven by climbing bond yields, have led to increased borrowing costs, discouraging homebuyers and prolonging the housing market slump. – Despite a slight rise in home sales in November, 2024 is expected to be the worst year for home sales since 1995, with affordability concerns continuing to impact the market.
The average rate on a 30-year mortgage has surged to 7.04%, marking its highest level since May and its fifth consecutive weekly increase. This rise in borrowing costs has left homebuyers facing higher monthly payments, potentially pricing many out of the housing market and prolonging an already sluggish real estate landscape.
According to mortgage buyer Freddie Mac, the rate has steadily climbed from 6.93% last week and has seen a significant jump from 6.6% a year ago. The increase is largely driven by higher bond yields, particularly the yield on the U.S. 10-year Treasury, which has surged from 3.62% in mid-September to 4.61% this week. Higher bond yields often lead to higher mortgage rates, as lenders use these benchmarks to set their borrowing costs.
The rising cost of home loans is particularly impactful on first-time buyers and those looking to refinance their homes at a lower rate. For many, the monthly payments associated with higher mortgage rates could amount to hundreds of dollars more, making homeownership less affordable. This shift has already begun to cool down demand, with fewer buyers in the market and a prolonged national home sales slump.
In fact, sales of previously owned homes have risen slightly in recent months, but the housing market is still on track to report its worst year for home sales since 1995. Despite the slight uptick in sales in November, analysts warn that full-year sales figures could be disappointing, reflecting the sharp slowdown in activity. This decline has been fueled by the steady rise in mortgage rates, which began climbing following signals from the Federal Reserve last year.
The Fed’s decision to curb anticipated interest rate cuts, in response to stubbornly high inflation and economic uncertainties, has further contributed to higher borrowing costs. With inflation still above the central bank’s 2% target and economic policies under a new administration potentially fueling costs, the rise in mortgage rates seems likely to persist.
For prospective homebuyers, these higher borrowing costs mean that affordability continues to shrink, particularly in an environment of rising home prices and limited housing inventory. Many are now opting to hold off on purchasing until either rates stabilize or decline.
Overall, the real estate market appears poised for continued challenges in 2025, as elevated mortgage rates and affordability concerns weigh on buyer demand and slow down housing market recovery. The outlook remains uncertain, with potential policy shifts and economic pressures playing a significant role in determining the future course of rates and housing activity.
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME).
“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding the active component—tumstatin—to integrin receptors that play a crucial role in disease pathogenesis,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. “OCU200 holds the promise to benefit all DME patients, including the 30-40% of patients who do not respond to current anti-VEGF therapies.”
The OCU200 Phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in three cohorts: low dose (0.025 mg), medium dose (0.05 mg), and high dose (0.1 mg). All subjects will receive a total of two intravitreal injections of OCU200 six weeks apart. Patient follow-up will take place up to three months after the last injection.
Approximately 12 million people in the United States and 130 million people worldwide are affected by DME, DR or wet AMD. Patients affected by these diseases share common symptoms, such as blurriness in vision and progressive vision loss as the disease progresses. The formation of fragile and leaky new blood vessels leads to fluid accumulation in and around the retina, causing damage to vision.
“I am seeing an increasing rate of vision-threatening diseases associated with diabetes at my clinic and am eager to provide a new therapeutic option to these patients,” said Dr. David Almedia, Vitreoretinal Surgeon and Clinician Scientist, President and CEO of Erie Retina Research, and Founder and President of Case X Global in Erie, Pennsylvania. “There remains a considerable unmet medical need for DME and DR patients with currently available anti-VEGF treatments.”
OCU200 is a recombinant fusion protein that consists of two parts connected by a linker: tumstatin, the active component, acts as an anti-inflammatory, anti-VEGF agent by binding to integrin receptors; and transferrin, which targets the drug to the choroid and retina by binding transferrin receptors on endothelial cells. These features will potentially enable OCU200 to reduce the vascular permeability, inflammation, and neovascularization that drive the pathophysiology of DME, DR, and wet AMD at a significantly lower dose compared to currently approved therapies.
“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief Medical Officer at Ocugen. “OCU200 brings an innovative biologic candidate to Ocugen’s ophthalmology portfolio targeting blindness diseases.”
The Company intends to pursue approval to use OCU200 as a first-line therapy for DME, DR, and wet AMD.
About Ocugen, Inc. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements Thispressreleasecontainsforward-lookingstatementswithinthemeaningofThePrivateSecuritiesLitigationReformActof1995,including,butnot limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines,whicharesubjecttorisksanduncertainties.Wemay,insomecases,usetermssuchas “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including,butnotlimitedto,therisksthatpreliminary,interimandtop-lineclinicaltrialresultsmaynotbeindicativeof,andmaydifferfrom,finalclinical data;the ability of OCU200 to perform in humans in a manner consistent with nonclinical or preclinical study data;thatunfavorablenewclinicaltrialdatamayemergeinongoingclinicaltrialsorthroughfurtheranalysesofexistingclinicaltrialdata;thatearlier non-clinicalandclinicaldataandtestingofmaynotbepredictiveoftheresultsorsuccessoflaterclinicaltrials;andthatthatclinicaltrialdataare subject to differing interpretations and assessments, including by regulatory authorities.Theseandotherrisksanduncertaintiesaremorefully describedinourperiodicfilingswiththeSecuritiesandExchangeCommission(SEC),includingtheriskfactorsdescribedinthesectionentitled“Risk Factors”inthequarterlyandannualreportsthatwefilewiththeSEC.Anyforward-lookingstatementsthatwemakeinthispressreleasespeakonlyas ofthedateofthispressrelease.Exceptasrequiredbylaw,weassumenoobligationtoupdateforward-lookingstatementscontainedinthispress release whether as a result of new information, future events, or otherwise, after the date of this press release.
Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Commercial expansion. On January 15th, the company announced that it will begin supplying its products to real estate developer Jeremiah Baron Companies. The developer has mixed-use residential and commercial projects underway in Florida. The partnership is expected to encompass approximately 1,000 units, which we believe equates to roughly 30,000 receptacles.
Seeding for the future. The company will initially supply receptacles to the developer, followed by plug-in products in the later stages of development, such as chandeliers, ceiling fans, and others. Importantly, the company’s fixtures, which plug into the receptacles, sell at higher prices. As such, we expect initial revenue impacts from the partnership to be modest, followed by a more meaningful impact when the units are ready for the installation of plug-in products. We anticipate that the development of the mixed-use project will extend into 2026.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Key Points: – Over 3.2 million electrified vehicles sold in 2024 – Tesla maintains EV leadership despite market share drop to 49% – Traditional combustion engine sales fall below 80% for first time
The U.S. automotive industry achieved a significant milestone in 2024, with electric and hybrid vehicles reaching 20% of the total market share for the first time, according to new data from Motor Intelligence. This marks a turning point in the evolution of consumer preferences, signaling a transition toward sustainable transportation options. While the shift to electrified vehicles has been slower than expected by some industry analysts, the data confirms that the momentum behind electrification is undeniable.
A total of more than 3.2 million electrified vehicles were sold last year, with hybrid vehicles—including plug-in models—accounting for 1.9 million units, and pure electric vehicles (EVs) making up 1.3 million sales. This surge has driven traditional internal combustion engine vehicles below the 80% market share threshold for the first time in modern automotive history, further emphasizing the growing importance of electrification in the U.S. automotive sector.
Tesla remains the dominant force in the EV market, despite a slight decline in its market share from 55% in 2023 to around 49% in 2024. While this drop may raise some eyebrows, it highlights the expanding competitiveness in the EV space rather than a downturn in Tesla’s performance. In fact, Tesla’s Model Y and Model 3 retained their positions as the bestselling electric vehicles in the U.S., continuing to set the pace for the industry.
The shift in Tesla’s market share also reflects an influx of new competitors entering the EV market. Hyundai Motor Group, including Kia, secured second place with 9.3% of the market, followed by General Motors at 8.7%, Ford at 7.5%, and BMW at 4.1%. This competition is reshaping the investment landscape, with traditional automakers like Ford and GM making aggressive pushes into the EV market, while luxury brands like BMW tap into the demand for high-end electrified models.
The evolving EV market is creating both opportunities and challenges for investors. The increasing competition, driven by both established automakers and new entrants, is a key factor reshaping the investment dynamics within the electric vehicle sector. Companies that are able to secure significant market share in the EV space, such as Tesla, GM, and Hyundai, are well-positioned to capitalize on the ongoing transition. At the same time, investors must remain vigilant to the competitive pressures that could impact individual companies’ performance, especially as the market continues to mature.
The 2024 data shows that the pace of electrification is accelerating, with over 68 mainstream EV models tracked by Cox’s Kelley Blue Book, and 24 of them showing year-over-year sales growth. The number of new models entering the market (17 in 2024) reflects the increasing commitment of manufacturers to the electric vehicle sector. Yet, it also underscores the need for companies to innovate and differentiate themselves in a crowded marketplace.
Looking ahead, the outlook for 2025 is promising. With projections for EV sales to potentially hit 10% of all new vehicle sales, and electrified vehicles (EVs and hybrids) possibly making up 25% of all new cars sold, the industry is poised for continued growth. However, the investment landscape could be impacted by policy changes, such as the potential reconsideration of the $7,500 federal tax credit for EVs under a new administration. Any changes to such incentives could influence future adoption rates and, in turn, investor sentiment in the electric vehicle market.
In conclusion, the electric vehicle market is undergoing a profound transformation, reshaping the U.S. automotive industry and the broader investment landscape. As more consumers make the switch to electrified vehicles and new players enter the market, investors will need to stay informed and strategically assess the opportunities and risks associated with this rapidly evolving sector.
The potential sale of TikTok’s U.S. operations is making waves across the business and investment community. With an estimated valuation of $40 billion to $50 billion, TikTok represents a significant opportunity and challenge for prospective buyers and investors. ByteDance’s consideration of selling TikTok’s U.S. unit is rooted in geopolitical tensions and national security concerns, making the situation both complex and impactful for markets.
Key Highlights of the Sale Scenario
Valuation and User Base: TikTok boasts a U.S. monthly mobile user base of 115 million, surpassing platforms like Snapchat and Pinterest, but trailing Instagram. This broad user base underpins its projected $50 billion valuation, though geopolitical issues and the absence of its proprietary recommendation algorithm in any sale could weigh on its appeal.
Potential Buyers: Among those reportedly interested are Elon Musk, whose acquisition would likely face intense regulatory scrutiny, and a consortium led by billionaire Frank McCourt and Kevin O’Leary, who estimate a lower bid of $20 billion.
Regulatory and Geopolitical Risks: The Supreme Court’s pending decision on banning TikTok in the U.S. and the Biden administration’s national security concerns pose significant uncertainties. These factors could impact valuations and the terms of any deal.
For investors, TikTok’s potential sale and the broader regulatory environment present both opportunities and risks:
Advertising Revenue Growth: TikTok has quickly become a dominant force in digital advertising. Companies expanding their ad spend on social platforms might find TikTok, under new ownership, a critical avenue for growth. A buyer capable of navigating regulatory concerns could unlock further advertising revenue potential, benefiting both private equity investors and public markets.
Impact on Competitors: Platforms like Instagram, Snapchat, and Pinterest might experience shifts in user engagement and ad revenue depending on the outcome of TikTok’s sale or a potential U.S. ban. Stock prices of these competitors could be directly affected by how TikTok’s future plays out.
Public Market Opportunities: If TikTok’s U.S. operations were to go public under a new owner, investors could gain direct exposure to one of the fastest-growing social media platforms. However, this would depend on resolving regulatory and national security concerns.
Regulatory Oversight: Heightened scrutiny of data privacy and national security may impact other tech companies reliant on foreign ownership or data-driven business models. This could lead to increased regulatory risks across the sector, affecting valuations and investor sentiment.
A forced sale of TikTok would send ripples through the broader market. Media and tech companies may see volatility as they adjust to potential competitive shifts, while private equity firms and institutional investors eye strategic opportunities.
Moreover, any large-scale acquisition of TikTok could spur merger and acquisition (M&A) activity in the tech sector, as companies reconfigure their strategies to align with changing market dynamics.
The fate of TikTok’s U.S. operations holds significant implications for investors, social media companies, and the stock market. Whether ByteDance chooses to sell or the Supreme Court enforces a ban, the outcome will shape the competitive landscape of digital media and advertising. For investors, the situation underscores the importance of monitoring regulatory developments, evaluating sector-specific risks, and being prepared to act on emerging opportunities.
As the story unfolds, it will not only test TikTok’s resilience but also provide valuable lessons for navigating geopolitical and regulatory challenges in today’s interconnected global markets.
Key Points: – December’s core Consumer Price Index (CPI) rose by 0.2% month-over-month, indicating a slight deceleration in inflation. – Federal Reserve officials are expected to maintain the current interest rates at the January policy meeting. – Concerns persist about achieving the Fed’s 2% inflation goal amid uncertainties in fiscal and regulatory policies.
Fresh inflation data released Wednesday is likely to keep the Federal Reserve on pause during its next policy meeting this month, even though a new reading did show some signs of easing.
On a “core” basis, which eliminates the more volatile costs of food and gas, the December Consumer Price Index (CPI) climbed 0.2% over the prior month, a deceleration from November’s 0.3% monthly gain. On an annual basis, prices rose 3.2%. It was the first drop on a core basis after three months of being stuck at 3.3%.
“This latest inflation reading confirms a Fed rate cut skip at the January FOMC meeting,” said EY chief economist Gregory Daco. The new print “won’t change expectations for a pause later this month, but it should curb some of the talk about the Fed potentially raising rates,” said Ellen Zentner, chief economic strategist for Morgan Stanley Wealth Management. The Fed next meets on Jan. 28-29, and investors are nearly unanimous in their view the central bank will leave rates unchanged after reducing them by a full percentage point in late 2024.
“We are making progress on inflation, it’s just very slow,” former Federal Reserve economist Claudia Sahm told Yahoo Finance Wednesday. “Cuts are not coming later this month, but that doesn’t mean they aren’t coming later this year.”
New York Fed president John Williams said after the CPI release that “while I expect that disinflation will progress, it will take time, and the process may well be choppy.” The economic outlook, he added, “remains highly uncertain, especially around potential fiscal, trade, immigration, and regulatory policies” — a reference to possible changes that could happen as part of the incoming Trump administration. Lots of Fed officials in recent weeks have been urging caution on future rate cuts.
In fact, the Fed’s December meeting minutes showed officials believed inflation could take longer than anticipated to reach their 2% goal, citing stickier-than-expected inflation data since past fall and the risks posed by new policies of Trump 2.0. They noted “the likelihood that elevated inflation could be more persistent had increased,” according to the minutes, even though they still expected the Fed to bring inflation down to its 2% goal “over the next few years.” Several members of the Fed even said at that meeting that the disinflationary process may have stalled temporarily or noted the risk that it could.
The elevated inflation concerns help explain why Fed officials in December reduced their estimate of 2025 rate cuts to two from a previous estimate of four. U.S. Federal Reserve Chair Jerome Powell speaks during a press conference where he announced the Fed had cut interest rates by a quarter point following a two-day meeting of the Federal Open Market Committee on interest rate policy in Washington, U.S., December 18, 2024. REUTERS/Kevin Lamarque.
Inflation could show new signs of progress in year-over-year comparisons later in 2025’s first quarter since in 2024 inflation spiked back up before declining again. Fed governor Michelle Bowman may be the most worried of the Fed officials, saying last week that she could have backed a pause in interest rates last month but supported a cut as the “last step” in the central bank’s “policy recalibration.”
Kansas City Fed president Jeff Schmid, a voting FOMC member this year, said, “I believe we are near the point where the economy needs neither restriction nor support, and that policy should be neutral.” Schmid said he is in favor of adjusting rates “gradually,” noting that the strength of the economy allows the Fed to be patient. Boston Fed president Susan Collins, another voting member this year, also called for a gradual approach.
“With policy already closer to a more neutral stance, I view the current nature of uncertainty as calling for a gradual and patient approach to policymaking,” Collins said. But DWS Group head of fixed income George Catrambone said the new numbers released Wednesday provided a “sigh of relief” for the Fed. But there is still a lot of uncertainty ahead, as new policies from the Trump administration may affect the outlook. As to when the Fed may first cut rates in 2025, “if we don’t see it by Jackson Hole, it’s not coming,” Catrambone added, referring to an annual Fed event that takes place in late August.
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy
Atlanta, GA, January 15, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing innovative immunotherapies and vaccines for cancer and infectious diseases, announced significant progress in advancing Gedeptin as a cancer therapy. Gedeptin, based on a Gene-Directed Enzyme Prodrug Therapy (GDEPT) platform, employs a targeted approach to deliver therapeutic agents directly to tumor sites. The result of this approach is the localized production of a potent anti-cancer agent(s) within the tumor microenvironment, while minimizing systemic exposure and the potential for associated side effects.
Following a review of the data from the completed Phase 1 single-cycle and Phase 1/2 multi-cycle Gedeptin trials among patients with advanced Head & Neck (H&N) tumors, GeoVax has decided to initiate a Phase 2 clinical study, evaluating neoadjuvant Gedeptin therapy in combination with an approved immune check point inhibitor (ICI) in 1st recurrent H&N cancer scheduled for resection with curative intent.
Therapy Potential and Market Opportunity
Gedeptin has been granted Orphan Drug Designation by the U.S. FDA for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, underscoring its potential to address significant unmet medical needs.
“Preclinical data suggest that Gedeptin/fludarabine can enhance the activity of ICIs in treatment of solid tumors. Our upcoming Phase 2 trial will investigate this approach as a neoadjuvant therapy for patients with first recurrence head and neck cancer. We believe this will lead to increased tumor response and decreased recurrence rates in these patients,” said David Dodd, Chairman and CEO of GeoVax. “Based on the data generated to date, this combination has the potential to address multiple solid tumor indications, and represents a significant medical and commercial opportunity, if approved.”
David Dodd added, “We are entering an exciting phase of clinical development with Gedeptin, and our team remains committed to advancing this innovative therapy to deliver life-changing benefits for cancer patients worldwide.”
Advancing Clinical Development
The upcoming Phase 2 trial will evaluate the efficacy of Gedeptin in combination with ICIs in patients with first-recurrence head and neck cancer. Key endpoints will include pathologic response rates and overall treatment outcomes. GeoVax plans to initiate trial activities mid-year and partner with leading academic oncology centers.
A Transformative Year Ahead
GeoVax projects significant milestones in 2025, with Gedeptin expected to play a key role in delivering transformative cancer therapies. Beyond head and neck cancers, the company plans to explore Gedeptin’s potential applications across other solid tumor types.
GeoVax’s CEO, David Dodd, will present the Company’s 2024 progress and outlook for 2025 at the Emerging Growth Conference: January 16, 2025, at 2:35 PM ET.
For more information on GeoVax’s portfolio and developments, please visit www.geovax.com.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
As SKYX Continues to Grow its Market Penetration, it is Expected to Supply Developer Jeremiah Baron Companies Products to a Total of 1000 Mixed-Use Residential and Commercial Units
The Products that are Expected to be Supplied to the Mixed-Use Project will include Ceiling Outlet Receptacles, Smart Plug & Play Platform Products including Lighting, Ceiling Fans, Recessed Lights, EXIT Signs, Emergency Lights, Down Lights, and Indoor and Outdoor Wall Lights
MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive smart platform technology company with more than 97 issued and pending patents globally and over 60 lighting and home décor websites, announces that it will start supplying its products to developer Jeremiah Baron Companies for 140 commercial units representing the initial rollout of overall projects.
During the course of the projects, SKYX is expected to deliver tens of thousands of its products, representing a variety of its advanced and smart platform technology plug & play products. Delivery is expected to start in January 2025 and to continue throughout the construction of the developments in the state of Florida.
Rani Kohen, Founder/Inventor and Executive Chairman, of SKYX Platforms, said: “This is another step towards our goal of making homes and buildings become advanced, safe, and smart as the new standard. We are eager to continue to demonstrate our advanced smart platform technology’s ability to instantly make homes and buildings become advanced, safe, and smart.”
Jeremiah Baron, CEO and Founder of Jeremiah Baron Companies, said: “We are looking forward to developing and providing safe, smart, and advanced residential and commercial projects utilizing SKYX’s game changing technologies. This enables us to create substantial added value to our homes and buildings as well as for our customers, while realizing significant cost and time savings.” About Jeremiah Baron, click here: https://jeremiahbaroncompanies.com
About SKYX Platforms Corp.
As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 97 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.
Forward-Looking Statements
Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.
